Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Eisai Co Ltd Phase III trial shows lenvatinib meets primary endpoint of progression free survival benefit in treatment of redioiodine-refractory differentiated thyroid cancer


Sunday, 2 Feb 2014 10:30pm EST 

Eisai Co Ltd:Says the Phase III SELECT trial of lenvatinib, an investigational selective tyrosine kinase inhibitor with a novel binding mode, the first-in-class of its kind, met its primary endpoint.Says compared to placebo, lenvatinib showed a statistically improvement in progression free survival in patients with radioiodine-refractory differentiated thyroid cancer. 

Related Company News

Company Quote

41.51
0.26 +0.63%
11 Jul 2014